GlassScriptPhysician profile
Vivien M B Tham
NPI 1740372234
$9,270.06
in general payments reported to CMS, 2019-2025
20 companies · $1,801 in 2025
The $1,801 reported for 2025 was more than what 87% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,759 · 2020: $166 · 2021: $443 · 2022: $808 · 2023: $1,305 · 2024: $1,989 · 2025: $1,801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,094.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,869.14 | 2019-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Alcon Vision LLC | $1,712.53 | 2019-2025 | Clareon, Argos, Hydrus Microstent |
| Amgen INC. | $862.92 | 2024-2025 | Tepezza |
| Sight Sciences, INC. | $641.80 | 2022-2025 | Omni Surgical System, Sion Surgical Instrument |
| Bausch & Lomb Americas INC. | $447.93 | 2022-2025 | Envista Mx60 Iol, Vyzulta, Envista Aspire Iol |
| Horizon Therapeutics Plc | $442.58 | 2022-2023 | Tepezza |
| Abbvie INC. | $439.11 | 2022-2025 | |
| Dompe US, INC. | $425.12 | 2019-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $266.61 | 2024-2025 | Xdemvy |
| Allergan, INC. | $245.15 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $197.53 | 2023-2024 | Acthar |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $163.33 | 2019-2021 | |
| Genentech USA, INC. | $141.50 | 2022 | |
| Rxsight INC | $119.56 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Injector Handpiece |
| Aerie Pharmaceuticals, INC. | $99.84 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $75.00 | 2025 | |
| Harrow Eye, LLC | $51.46 | 2025 | Vevye, Flarex, Iheezo |
| Ani Pharmaceuticals, INC. | $31.78 | 2024 | Purified Cortrophin Gel |
| Oyster Point Pharma, INC. | $24.22 | 2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $12.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivien Tham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.